EP1102788A4 - Prevention and treatment of viral disease - Google Patents
Prevention and treatment of viral diseaseInfo
- Publication number
- EP1102788A4 EP1102788A4 EP99945011A EP99945011A EP1102788A4 EP 1102788 A4 EP1102788 A4 EP 1102788A4 EP 99945011 A EP99945011 A EP 99945011A EP 99945011 A EP99945011 A EP 99945011A EP 1102788 A4 EP1102788 A4 EP 1102788A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- prevention
- treatment
- viral disease
- viral
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9510598P | 1998-08-03 | 1998-08-03 | |
US95105P | 1998-08-03 | ||
US14180699P | 1999-06-29 | 1999-06-29 | |
US141806P | 1999-06-29 | ||
PCT/US1999/017487 WO2000008043A2 (en) | 1998-08-03 | 1999-08-03 | Prevention and treatment of viral disease |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1102788A2 EP1102788A2 (en) | 2001-05-30 |
EP1102788A4 true EP1102788A4 (en) | 2002-08-28 |
Family
ID=26789760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99945011A Withdrawn EP1102788A4 (en) | 1998-08-03 | 1999-08-03 | Prevention and treatment of viral disease |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1102788A4 (en) |
JP (1) | JP2002522448A (en) |
KR (1) | KR20010085326A (en) |
CN (1) | CN1321165A (en) |
AU (1) | AU5771599A (en) |
BR (1) | BR9912732A (en) |
CA (1) | CA2338983A1 (en) |
IL (1) | IL141211A0 (en) |
WO (1) | WO2000008043A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003523721A (en) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | Polynucleotides encoding antigenic HIVC-type polypeptides, polypeptides, and uses thereof |
FR2789590B1 (en) * | 1999-02-15 | 2003-01-17 | Inst Rech Developpement Ird | IMMUNOGENIC COMPOSITIONS FOR USE AS VACCINES |
EP1130089A1 (en) * | 2000-02-17 | 2001-09-05 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Composition comprising membrane virus subviral target and fusion particles and vaccine comprising said composition |
US7033593B2 (en) | 2000-09-22 | 2006-04-25 | Duke University | Immunogen comprising an HIV envelope protein, a ligand and H2 peptide |
MXPA03002480A (en) | 2000-09-22 | 2004-05-24 | Univ Duke | Immunogen comprising ligand bound hiv envelpe protein. |
ES2260416T3 (en) * | 2001-01-05 | 2006-11-01 | Sanofi Pasteur | POLYPEPTIDE INDUCING ANTIBODIES THAT NEUTRALIZE HIV. |
FR2819256B1 (en) * | 2001-01-05 | 2004-04-30 | Aventis Pasteur | POLYPEPTIDE INDUCING HIV NEUTRALIZING ANTIBODIES |
US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
GB201412494D0 (en) | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000103A1 (en) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
WO1993005147A1 (en) * | 1991-08-30 | 1993-03-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Defective interfering hiv particles with chimeric cd4-env |
-
1999
- 1999-08-03 WO PCT/US1999/017487 patent/WO2000008043A2/en not_active Application Discontinuation
- 1999-08-03 CA CA002338983A patent/CA2338983A1/en not_active Abandoned
- 1999-08-03 EP EP99945011A patent/EP1102788A4/en not_active Withdrawn
- 1999-08-03 BR BR9912732-6A patent/BR9912732A/en not_active IP Right Cessation
- 1999-08-03 IL IL14121199A patent/IL141211A0/en unknown
- 1999-08-03 AU AU57715/99A patent/AU5771599A/en not_active Abandoned
- 1999-08-03 CN CN99811641A patent/CN1321165A/en active Pending
- 1999-08-03 JP JP2000563676A patent/JP2002522448A/en active Pending
- 1999-08-03 KR KR1020017001483A patent/KR20010085326A/en not_active Application Discontinuation
Non-Patent Citations (5)
Title |
---|
LACASSE ET AL.: "Fusion-competent vaccines: Broad neutralization of primary isolates of HIV", SCIENCE, vol. 283, 15 January 1999 (1999-01-15), pages 357 - 362, XP002120812 * |
NUNBERG, J.: "Retraction", SCIENCE, vol. 296, 10 May 2002 (2002-05-10), pages 1025 * |
THALI ET AL.: "Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding", J. VIROLOGY, vol. 67, no. 7, July 1993 (1993-07-01), pages 3978 - 3988, XP000579277 * |
WHITE-SCHARF: "Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization", VIROLOGY, vol. 192, 1993, pages 197 - 206, XP002203539 * |
WYATT & SODROSKI: "The HIV-1 envelope glyycoproteins: fusogens, antigens and immunogens", SCIENCE, vol. 280, 19 June 1998 (1998-06-19), pages 1884 - 1888, XP002203540 * |
Also Published As
Publication number | Publication date |
---|---|
AU5771599A (en) | 2000-02-28 |
JP2002522448A (en) | 2002-07-23 |
WO2000008043A3 (en) | 2000-05-11 |
KR20010085326A (en) | 2001-09-07 |
EP1102788A2 (en) | 2001-05-30 |
CN1321165A (en) | 2001-11-07 |
CA2338983A1 (en) | 2000-02-17 |
BR9912732A (en) | 2001-11-27 |
WO2000008043A2 (en) | 2000-02-17 |
IL141211A0 (en) | 2002-02-10 |
WO2000008043A9 (en) | 2001-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG111083A1 (en) | Prevention and treatment of amyloidogenic disease | |
GB2368794B (en) | Prevention and treatment of amyloidogenic disease | |
HUP0201205A2 (en) | Prevention and treatment of amyloidogenic disease | |
IL132003A0 (en) | Antimicrobial prevention and treatment of human immundeficiency virus and other infectious diseases | |
IL129352A0 (en) | Benzimidazole-2- carbamates for the treatment of viral infections and cancer | |
EP1109580A4 (en) | Methods for treating or preventing viral infections and associated diseases | |
EP1115286A4 (en) | Methods for treating or preventing viral infections and associated diseases | |
HK1043019B (en) | Compositions and methods for prevention and treatment of protozoal disease | |
DE69836209D1 (en) | PREVENTION AND TREATMENT OF HEPATOCELLULAR CANCER | |
IL138692A0 (en) | Treatment and prevention of vascular disease | |
IL141211A0 (en) | Prevention and treatment of viral disease | |
EP1173189A4 (en) | Asialocytokines and treatment of liver disease | |
EP1107778A4 (en) | Treatment of disease states | |
EP0833641A4 (en) | Treatment and prevention of prostatic disease | |
GB9516572D0 (en) | Prevention and/or treatment of disease | |
GB0016197D0 (en) | Treatment and prevention of disease | |
GB0030865D0 (en) | Treatment and prevention of disease | |
GB0030866D0 (en) | Treatment and prevention of disease | |
ZA9810932B (en) | Prevention of and treatment of amyloidogenic disease. | |
IL141880A0 (en) | Treatment of depression | |
AU2003203740A1 (en) | Prevention and treatment of amyloidogenic disease | |
GB9726745D0 (en) | Treatment of medical conditions | |
GB9710054D0 (en) | Treatment of diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010302 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07H 21/04 A, 7A 61K 48/00 B, 7A 61K 39/395 B, 7C 12N 1/20 B, 7A 61K 39/21 B, 7C 07K 14/16 B, 7C 12N 15/62 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020711 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030302 |